Bose CK. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
Med Oncol 2022;
39:67. [PMID:
35478274 DOI:
10.1007/s12032-022-01672-5]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Accepted: 01/28/2022] [Indexed: 12/01/2022]
Abstract
In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as shown in post-approval data published. The context of such approvals and controversies is discussed briefly.
Collapse